In this context, IDH1 and IDH2 mutations, 1p/19q codeletion, TERT promoter mutation, as well as ATRX, TP53, and CDKN2A/B alterations are of critical importance for gliomas [6,7]. Here, TP53 is linked to central nervous system cancer.